FDA Import Alerts & DWPE for Medical Devices: The Border Gate

Guide to FDA Import Alerts and Detention Without Physical Examination (DWPE) for medical devices. Learn the Red List removal and petition workflow.

Scenario: Gating Medical Device Shipments at the U.S. Border

Imagine your company is a foreign manufacturer of surgical gloves, facepiece respirators, or diagnostic imaging components. You have signed a lucrative distribution agreement with a U.S. partner. The first large container of medical devices has arrived at the Port of Los Angeles.

Your logistics team is preparing for clearance when they receive a notification from U.S. Customs and Border Protection (CBP) and the FDA: "Your shipment has been detained under Section 801 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) without physical examination."

You check the FDA’s database and find that your facility has been placed on an FDA Import Alert Red List. Your U.S. distributor cannot access the inventory. The container is held in a customs warehouse, accruing storage fees daily. If you cannot prove compliance within 45 days, the shipment must be destroyed or re-exported. Even worse, every future shipment from your facility will be automatically detained at the border.

This guide provides a comprehensive, operational playbook for foreign manufacturers and importers of medical devices. It explains how FDA Import Alerts and Detention Without Physical Examination (DWPE) work, details the key device-specific alerts (including the latest 2026 updates), and outlines the step-by-step remediation process to get off the Red List.

What are FDA Import Alerts and How Does DWPE Work?

Under Section 801(a)(3) of the FD&C Act, the FDA has the authority to refuse admission to any imported medical device that "appears" to be adulterated, misbranded, or in violation of U.S. laws. The agency does not need to physically inspect a shipment or analyze a sample to detain it. If the FDA has "historical evidence or other information" suggesting a firm's products are non-compliant, it can issue an Import Alert.

An Import Alert authorizes Detention Without Physical Examination (DWPE). When a firm is placed on an Import Alert's Red List, all incoming shipments of the specified products from that firm are automatically detained at the U.S. port of entry. The burden of proof shifts entirely to the importer: the shipment remains detained until the importer presents evidence to the FDA proving that the specific shipment complies with U.S. regulations.

The Import Alert Lists:

The Red List: A directory of specific foreign manufacturers, shippers, and products subject to DWPE. If your firm is on the Red List, you are flagged for automatic detention.
The Green List: Applies to alerts where the FDA has placed an entire country or region under surveillance, but has exempted specific firms that have demonstrated a continuous history of compliance. Being on the Green List is a positive status that allows you to bypass general DWPE.
The Yellow List: A transition list for firms under active review. The FDA may place a firm on the Yellow List while evaluating their petition for removal from the Red List or addition to the Green List.

Summary of Key Medical Device Import Alerts

The FDA organizes Import Alerts by industry and product type. Medical-device-specific alerts primarily cluster in the 89-series (Devices) and the 80-series (General Hospital and Personal Use).

The table below summarizes the most critical import alerts gating medical device imports, incorporating updates from recent 2026 reviews:

Alert Number	Alert Name & Description	Underlying U.S. Regulation	2026 Update Status & Scope
Import Alert 89-08	Detention of devices without an approved PMA or IDE, or without 510(k) clearance.	21 CFR Part 807 (Registration/Listing), Section 510(k) or 515 of the FD&C Act.	Updated July 2026: Red List publications dated 07/14/2026 (country page) and 07/21/2026 (industry page), targeting uncleared devices across multiple origins.
Import Alert 89-04	Detention of devices from firms failing to meet device quality system requirements.	21 CFR Part 820 (Quality System Regulation / QMSR).	Updated July 2, 2026: Target list expanded following foreign facility audits that revealed critical CAPA/validation failures.
Import Alert 99-34	Detention of drugs or devices from firms without valid registration and/or listing.	21 CFR Part 807 (Establishment Registration).	Updated July 13, 2026: Automatic border detention for foreign firms with expired or unpaid annual registrations.
Import Alert 89-16	Detention of medical devices from firms refusing FDA foreign establishment inspection.	Section 704 or 801(a) of the FD&C Act.	Current (Updated Sept 11, 2025): Automatic Red List placement for any facility that delays, limits, or refuses an audit.
Import Alert 80-04	Surveillance and DWPE of Surgeon's and Patient Examination Gloves.	21 CFR Part 800.20 (Adulteration/Barrier integrity testing).	Updated July 16, 2026: Implemented stricter sampling controls and updated the Red List for glove manufacturers.
Import Alert 80-06	Detention of medical devices with false or misleading labeling.	Section 502(a) of the FD&C Act (Misbranding).	Current (Updated March 6, 2025): Focuses on fraudulent claims, particularly for software and diagnostic wellness kits.
Import Alert 89-18	Detention of filtering facepiece respirators (N95s/KN95s) with deficient filtration.	Section 501(c) or 502(j) of the FD&C Act.	Current: Automatic detention of respirators failing NIOSH or FDA particulate filtration standards.
Import Alert 95-04	Detention of electronic products failing to meet radiation performance standards.	21 CFR Part 1000-1050 (Performance Standards for Electronic Products).	Current: Targets laser-containing medical devices and x-ray systems lacking proper certification filings.

Deep Dive into Key Device Import Alerts

1. Import Alert 89-08: Unapproved or Uncleared Devices

Import Alert 89-08 is a catch-all gate for devices that lack proper marketing authorization. The FDA places firms on this Red List when border officials detect shipments of devices that require a 510(k) clearance, a Premarket Approval (PMA), or an Investigational Device Exemption (IDE) but do not have one.

The 2026 Updates: This alert is highly active. FDA published Red List updates for 89-08 on July 14, 2026 and again on July 21, 2026 — the publish dates shown on the accessdata country and industry pages — reflecting continued additions of uncleared-device firms across multiple countries of origin. Because the Red List changes with each publication, manufacturers should check the live alert before relying on any snapshot.
The Regulatory Trap: Many foreign firms attempt to import devices under generic, lower-risk product codes to bypass review. If the FDA's import system flags the shipment as matching a product code that requires a 510(k), and no matching pre-market clearance number is linked to the importer's listing, the shipment is immediately detained.

2. Import Alert 89-04: Quality System Failures (QSR / QMSR)

If a foreign manufacturer undergoes an on-site FDA inspection and receives a Form 483 with significant observations, followed by a formal Warning Letter detailing failures to comply with quality system regulations, the FDA does not wait for a recall to act. The agency will place the firm on Import Alert 89-04.

The 2026 Action: The Red List for 89-04 was revised on July 2, 2026. Foreign facilities making sterile disposables and high-risk capital parts were added after failing to address validation, design controls, and corrective actions (CAPA) during foreign audits.
The Resulting Gate: Once on this list, all devices from that facility are considered "adulterated" under Section 501(h) of the FD&C Act, and shipments are detained at the border, effectively shutting down U.S. distribution.

3. Import Alert 89-16: Refusing FDA Inspection

Under Section 704 of the FD&C Act, the FDA has the authority to inspect any facility registered to sell medical devices in the U.S. If a foreign manufacturer attempts to delay, limit, reschedule, or refuse an FDA inspection, the consequences are immediate.

The Red List Mechanism: The FDA places the firm on Import Alert 89-16 (originally established with guidance updated through September 11, 2025).
The Border Rule: Under this alert, "refusal" is interpreted broadly. If a manufacturer does not respond to the FDA's initial scheduling email within the required timeframe, or refuses to allow the inspector to view specific quality records, the FDA will treat it as a refusal and place the facility on the 89-16 Red List, detaining all shipments.

4. Import Alert 99-34: Expired or Deficient Registration and Listing

Under 21 CFR Part 807, all medical device establishments must register annually and list their active devices.

The 2026 Compliance Update: The FDA updated Import Alert 99-34 on July 13, 2026. This alert automates border enforcement: if a foreign firm fails to renew its registration during the October-December window, fails to pay the annual fee, or lists a device under an incorrect product code, the FDA's import database flags the error at entry, triggering automatic detention under 99-34.

5. Import Alert 80-04: Medical Gloves Barrier Defects

Medical examination and surgeon's gloves are subject to strict barrier integrity regulations to prevent pathogen transmission.

The July 2026 Update: On July 16, 2026, the FDA updated Import Alert 80-04, incorporating updated lists of manufacturers from Southeast Asia whose gloves failed water leak testing. Under this alert, the FDA conducts surveillance sampling of gloves at the port. If a sample fails the water leak test, the firm is added to the Red List, and all future shipments are subject to DWPE.

6. Import Alert 95-04: Radiation Safety Filings

Many modern medical devices contain lasers, x-ray components, or light-emitting components that emit radiation. These devices are subject to double oversight: standard medical device regulations (e.g. 510k) and FDA radiation safety standards governed by 21 CFR Parts 1000-1050.

The Accession Number Requirement: Before importing any radiation-emitting electronic product, manufacturers must submit a formal Product Report to the FDA's Center for Devices and Radiological Health (CDRH). The FDA issues a unique Accession Number confirming receipt and preliminary review of this report.
The 95-04 Gate: If the customs invoice or entry packet lacks a valid Accession Number, or if the manufacturer's radiation safety filing is incomplete, the shipment is detained at the border under Import Alert 95-04, even if the device has a valid 510(k) clearance.

The Border Detention Process

When a shipment is flagged for DWPE under an Import Alert, it enters a structured legal process governed by FDA Import Operations:

+--------------------------------------------------------------+
|                     1. ENTRY FILING                          |
|   Customs broker files entry data in CBP's ACE system;       |
|   flags match with an active Import Alert Red List.          |
+--------------------------------------------------------------+
                               |
                               v
+--------------------------------------------------------------+
|              2. ISSUANCE OF NOTICE OF DETENTION              |
|   FDA issues a formal Notice of Detention and Hearing to the  |
|   importer of record, detailing the violation charge.        |
+--------------------------------------------------------------+
                               |
                               v
+--------------------------------------------------------------+
|             3. THE 45-DAY RESPONSE WINDOW                    |
|   The importer has 45 calendar days to respond. They must    |
|   either submit evidence or request an extension.            |
+--------------------------------------------------------------+
                               |
                               v
+--------------------------------------------------------------+
|             4. TESTING & COMPLIANCE PETITION                 |
|   Importer submits private lab testing, truthing, or QMS     |
|   proof (under Section 801(a) Testimony) to show compliance.  |
+--------------------------------------------------------------+
                               |
                               v
+--------------------------------------------------------------+
|             5. FDA REVIEW & DISPOSITION                      |
|   FDA reviews testimony:                                     |
|   - If Accepted: Releases shipment (may take weeks).         |
|   - If Rejected: Issues Notice of Refusal; shipment must be  |
|     destroyed or re-exported within 90 days.                 |
+--------------------------------------------------------------+

During this detention, the importer is responsible for all warehouse, storage, and demurrage fees. A container stuck at the port can quickly accumulate thousands of dollars in fees, making rapid response critical.

The Financial Risk of Border Detentions

Border detentions are not just administrative headaches; they represent a major financial drain on the importer and the manufacturer. When a container is held at a U.S. port of entry under DWPE, the cargo enters a warehouse under customs bond.

Demurrage and Detention Fees: Shipping lines charge demurrage fees for containers left at the port terminal beyond the free days (typically 4 to 7 days). Demurrage fees start at approximately $150 to $300 per container per day and escalate the longer the container remains.
Customs Exam and Warehouse Fees: Importers must pay for moving the container to a Centralized Examination Station (CES) or a bonded warehouse. Warehousing fees can run from $500 to $1,500 per week depending on the volume and refrigeration requirements (critical for biological or diagnostic reagents).
Force Majeure and Contract Risks: Most distribution agreements contain clauses allowing the distributor to terminate the contract or refuse payment if shipments cannot clear customs within a set timeframe (e.g., 30 or 60 days). A border detention under an Import Alert can trigger these clauses, causing the manufacturer to lose the distributor and face lawsuits for breach of contract.

How to Get Off an FDA Import Alert Red List

Getting a single shipment released from detention is a temporary fix. To restore normal business operations, the foreign manufacturer must petition the FDA to be removed from the Import Alert Red List. This process is governed by the FDA's Division of Import Operations (DIO).

The remediation process requires a formal, structured petition:

Step 1: Correct the Root Cause

The FDA will not remove a firm from a Red List until the underlying violation is corrected.

If you are on 89-08 (uncleared devices), you must secure the appropriate 510(k) clearance or PMA approval.
If you are on 89-04 (quality system failures), you must implement a complete CAPA program, retrain staff, conduct internal audits, and submit a detailed response showing compliance with 21 CFR Part 820.
If you are on 89-16 (inspection refusal), you must formally contact the FDA scheduling team, agree to a date, and successfully undergo the on-site audit.
If you are on 99-34 (registration errors), you must update your establishment registration, pay outstanding fees, and list your devices correctly.

Step 2: Establish a Clean Shipping History

To prove that the corrections are durable, the FDA typically requires the firm to submit evidence from a series of consecutive, compliant shipments:

The Five-Shipment Rule: For most device import alerts (such as 80-04 gloves or general diagnostic equipment), the manufacturer must successfully ship at least five consecutive shipments to the U.S. that are detained, tested by an independent, third-party laboratory, and proven to comply with U.S. standards.
Sampling Protocol Standards: The testing must follow strict, statistically valid sampling guidelines. For example, for medical gloves under Import Alert 80-04, the private lab must sample the shipments according to the ANSI/ASQ Z1.4 standard (General Inspection Level II, single sampling plan for normal inspection) and perform water leak tests as specified in 21 CFR Part 800.20. The lab's chain of custody, raw data, and photographs of the testing setup must be documented in the petition.
Representativeness: The shipments must be commercially representative. You cannot ship five small boxes of sample devices over two days to clear the requirement. The shipments must span a reasonable period (e.g., several weeks or months) and reflect normal commercial volumes.
Third-Party Laboratories: The importer must hire a private laboratory to sample and test the detained shipments. The laboratory's sampling protocol, analytical methods, and final test reports must be submitted directly to the FDA as testimony.

Step 3: Submit the Removal Petition

Once you have corrected the violation and compiled the clean shipping history, you must submit a formal Import Alert Removal Petition to the FDA Division of Import Operations. The petition must include:

The name of the firm, FDA establishment registration number, and the specific Import Alert and Red List you are petitioning for.
A detailed description of the corrective actions taken to address the original violation (including engineering reports, updated SOPs, and employee training records).
Copy of the five consecutive clean entry packets, customs entry documents, and independent laboratory test reports.
A formal statement certifying that the firm is in compliance with all relevant U.S. food and drug laws.

Step 4: FDA Evaluation and Yellow List Transition

The Division of Import Operations reviews the petition, coordinating with the relevant center (such as the Center for Devices and Radiological Health - CDRH).

Timeline: The review process typically takes 3 to 6 months, depending on the complexity of the petition and DIO's backlog.
The Yellow List Phase: If the FDA finds the petition is complete but wants to verify ongoing compliance, they may temporarily move the firm to the Yellow List. During this phase, your shipments may still undergo close monitoring, but they are no longer subject to automatic detention.
Final Removal: Once the FDA is satisfied, they will issue a formal approval, remove the firm from the Red List, and update the public database.

How Import Alerts Connect to Broader Regulatory Requirements

Manufacturers often treat import compliance as a logistics issue, separate from their regulatory affairs department. This is a critical error. Import Alerts are the physical enforcement of domestic regulatory requirements:

Registration and Listing Linkage: Your U.S. Agent plays a key role here. Every foreign manufacturer must designate a U.S. Agent who acts as the primary contact for the FDA. If the FDA cannot contact your U.S. Agent, or if the agent fails to confirm their representation, the FDA will cancel your registration, triggering an automatic Import Alert 99-34 detention. (For details on structuring these obligations, see our FDA establishment registration and device listing guide).
QMSR and Audit Linkage: Under the FDA’s Quality Management System Regulation (QMSR), which harmonizes 21 CFR Part 820 with ISO 13485, foreign facilities must maintain a high level of audit readiness. If an audit reveals major non-conformities, or if you refuse an inspection, the border closes. For a detailed guide on surviving these inspections and aligning your documentation with compliance programs, refer to our playbook on FDA QMSR inspection preparation and compliance program.
Cross-Jurisdiction Comparison: While the U.S. uses Import Alerts and DWPE to block non-compliant imports at the border, the European Union enforces compliance through a decentralized network of Authorized Representatives and national competent authorities under the EU MDR. To compare the U.S. border enforcement model against the EU's importer obligations, see our guide on EU MDR importer and distributor obligations.

Frequently Asked Questions (FAQs)

Does FDA need to physically examine my shipment to detain it?

No. Under the DWPE mechanism authorized by Section 801 of the FD&C Act, if a foreign manufacturer or product is listed on an active Import Alert Red List, the shipment is detained automatically at the port based purely on the customs entry data. The FDA does not open the container or examine the packages unless the importer petitions for release and submits independent test data.

Can a device be detained for lacking 510(k) clearance even if it is not adulterated?

Yes. Under Section 502(o) of the FD&C Act, a medical device is considered misbranded if it is manufactured in an establishment that is not registered, if it is not listed, or if it lacks the required pre-market clearance or approval. Misbranding is a separate, independent legal basis for border detention and refusal of admission, regardless of whether the physical device is safe or free from contamination.

How long does it take to get off an FDA import alert Red List?

Getting off a Red List is a multi-month process. Once you have corrected the root cause and completed the required consecutive clean shipments (which can take several weeks or months), the FDA Division of Import Operations typically takes 90 to 180 days to review and approve the removal petition. Total remediation time from the initial detention to removal from the Red List averages 6 to 12 months.

Are device import alerts different from food and drug import alerts?

Yes, the FDA organizes its Import Alerts by industry sector. While food import alerts (like the 16-series for seafood or 21-series for pesticide residues) and drug alerts (like the 66-series for API quality) focus heavily on chemical and biological contamination, device import alerts (the 89-series and specific 80-series) focus primarily on pre-market clearances, quality system regulation (QMSR) compliance, establishment registration, and physical performance standards (e.g., glove barrier integrity or laser radiation safety).

Can a foreign manufacturer use a domestic consulting firm to file the petition?

Yes. Many foreign manufacturers hire U.S.-based regulatory consultants or legal counsel to represent them before the FDA Division of Import Operations. The consultant acts as the point of contact, ensures the petition is compiled according to DIO guidelines, coordinates with the private testing laboratory, and tracks the review status. However, the manufacturer's corporate officers must sign the formal certification statements included in the petition.

What happens if a re-exported shipment is returned to the U.S.?

If a shipment is refused admission and the importer chooses to re-export it rather than destroy it, the cargo must be physically exported from the U.S. under Customs supervision. The importer cannot simply ship it to a nearby foreign port (e.g. Mexico or Canada) and attempt to re-import it under a different customs entry number. Doing so constitutes a violation of customs laws and can lead to seizure of the goods, severe civil penalties, and criminal charges for smuggling.

Action Plan for Foreign Device Manufacturers and Importers

To minimize the risk of border detentions and manage Import Alert issues, implement the following four-step action plan:

Monitor Your Registration Status Monthly: Do not assume your annual registration renewal was successful. Have your regulatory team log into the FDA Unified Registration and Listing System (FURLS) monthly to verify that your establishment status is listed as "Active," all fees are paid, and your listed devices match your current product catalog.
Verify Your U.S. Agent's Contact Protocol: Ensure your designated U.S. Agent has a reliable, 24/7 protocol for forwarding FDA communications. If the FDA sends a notice of inspection scheduling to your U.S. Agent and they fail to forward it or respond within the required window, the FDA will register a refusal and place your facility on the 89-16 Red List.
Prepare a Port-Specific Customs Package: For every shipment, provide your customs broker with a comprehensive compliance packet, including your FDA establishment registration number, listed device numbers, the 510(k) clearance or PMA approval letter, and a copy of your commercial invoice. Proactive documentation helps prevent administrative delays in Customs' Automated Commercial Environment (ACE).
Engage Experienced Counsel for Red List Petitions: If your facility is placed on a Red List, do not draft the petition without regulatory expertise. Work with specialized counsel to structure your corrective action evidence, draft the Section 801(a) testimony, coordinate with an accredited private laboratory for sampling, and compile the petition according to DIO guidelines to ensure a successful first-pass review.